Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: ##STR00001## wherein: R.sup.1 and R.sup.2 are independently H, alkyl, or alkenyl; R.sup.3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R.sup.4 and R.sup.5 are independently a bond, alkylenyl, or alkenylenyl; each R.sup.6 and R.sup.7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C.sub.1-C.sub.6)alkyl, alkoxy, amino, COOH, CONH.sub.2, SO.sub.3H, PO.sub.3H.sub.2, CN, SH, NO.sub.2 and CF.sub.3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.

University of Pittsburgh--Of the Commonwealth System of Higher Education

Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases

Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).

multiple myeloma/قنب هندي

Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases

Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases

Cannabinoid receptor CB2 ligand 4-(aminomethyl)-N,N-dialkylanilines

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم